Our Product Pipeline
Explore our innovative therapies in development.
Baritiz 2 (Baricitinib)
Used to treat rheumatoid arthritis and severe COVID-19 by inhibiting JAK pathways to reduce inflammation.
Letrotiz 2.5 (Letrozole)
An aromatase inhibitor for hormone-sensitive breast cancer in postmenopausal women.
Methotiz 2.5 (Methotrexate)
Used for autoimmune diseases and cancers by inhibiting DNA synthesis in rapidly dividing cells.
Tizibus 2 (Busulfan)
An alkylating agent for chronic myeloid leukemia and bone marrow transplant conditioning.
Tizireg 40 (Regorafenib)
Multikinase inhibitor for colorectal cancer, GIST, and liver cancer.
Temotiz 20 (Temozolomide)
Oral chemotherapy for glioblastoma and anaplastic astrocytoma.
Cabotiz 20 (Cabozantinib)
Tyrosine kinase inhibitor for renal cell carcinoma and thyroid cancer.
Cabotiz 40 (Cabozantinib)
Higher dose formulation for advanced cancers including liver and kidney tumors.
Cabotiz 60 (Cabozantinib)
Used in metastatic cancer treatment targeting multiple kinases.
Tizialect 150 (Alectinib)
Treats ALK-positive non-small cell lung cancer, especially metastatic cases.
Brigatiz 90 (Brigatinib)
Kinase inhibitor for ALK-positive NSCLC after progression on crizotinib.
Crizotiz 250 (Crizotinib)
Used for ALK- or ROS1-positive NSCLC and certain lymphomas.
Erlotib 25 (Erlotinib)
EGFR inhibitor for NSCLC with EGFR mutations and pancreatic cancer.
Erlotib 100 (Erlotinib)
Intermediate dose for targeted cancer therapy in EGFR-positive tumors.
Erlotib 150 (Erlotinib)
Standard dose for advanced NSCLC and pancreatic cancer treatment.
Acalatiz 100 (Acalabrutinib)
BTK inhibitor for CLL, SLL, and mantle cell lymphoma.
Ibrutiz 140 (Ibrutinib)
Treats CLL, Waldenström’s macroglobulinemia, and cGVHD by blocking BTK signaling.
Tizivand 100 (Vandetinib)
Used for inoperable or metastatic medullary thyroid cancer.
Tizivand 300 (Vandetinib)
High-dose formulation for aggressive thyroid cancers.
Bicaltiz 50 (Bicalutamide)
Antiandrogen used in combination therapy for metastatic prostate cancer.
Tiziax 1 (Axitinib)
VEGF receptor inhibitor for advanced renal cell carcinoma.
shaping the future of healthcare
Resources
Corporate Office
Maligaun-5, Kathmandu,
Phone No: 01-5912699
Email: [email protected]
Factory
Tukucha-1, Nala, Banepa, Kavre,
Phone No: 011-411241
Email: [email protected]
© Copyright 2024 Tizig Pharma Pvt. Ltd. All rights reserved.